HEAL Initiative: Planning Studies for Initial Analgesic Development [Small Molecules and Biologics] (R61 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

The goal of this funding opportunity announcement (FOA) is to solicit Initial Analgesic Development R61 applications that propose 2-year exploratory/planning awards that are expected to enable a future application for RFA-NS-21-015 HEAL Initiative: Team Research - for Initial Translational Efforts in Non-addictive Analgesic Development [Small Molecules and Biologics] (U19 Clinical Trial Not Allowed).Thus, the limited scope of aims and approach of these applications are expected to establish a strong research team, feasibility, validity, or other technically qualifying results that support, enable, and/or lay the groundwork for a subsequent Team Research U19 application. These R61 awards will support the building of a research team to collect initial data and recruit additional collaborators. The application must include a plan for developing a strong research team, as well as a strategy to collect preliminary data linking putative therapeutic targets to the proposed pain indication and supporting the hypothesis that altering target activity will produce desirable outcomes for the disease.


  • Letter of Intent Due Date(s): 30 days prior to receipt date.
  • Application Due Date(s): July 19, 2021; Oct 13, 2021; June 9, 2022; Oct. 11, 2022; June 9, 2023; Oct. 10, 2023

RFA-NS-21-029 Expiration Date October 11, 2023

Agency Website



Amount Description

The direct costs for each year of the project may not exceed $500,000, including consortium costs.

Award Project Period: 2 years

      Funding Type





      Environmental & Life Sciences
      Medical - Basic Science
      Medical - Clinical Science
      Medical - Translational

      External Deadline

      October 10, 2023